Last edition
News about Drug Discovery & Development
GSK Reports Real-World Data Showing Strong Effectiveness of RSV Vaccine in Older Adults
New US and Denmark studies presented at ReSViNET 2026 show GSK’s RSV vaccine is associated with reduced hospitalisations and lower risk of severe cardiovascular and respiratory complications in adults aged 60 and above.
Drug Discovery & Development | 19/02/2026 | By News Bureau | 213
The global molecular diagnostics market is projected to reach USD 38.01 billion by 2034, according to a new report by Polaris Market Research. The study provides an in-depth assessment of market size, share, emerging trends, and growth forecasts from 2025 to 2034, highlighting the sector’s expanding role in modern healthcare.
Drug Discovery & Development | 19/02/2026 | By Darshana | 145
Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review
Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.
Drug Discovery & Development | 18/02/2026 | By News Bureau | 221
GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP
European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.
Drug Discovery & Development | 18/02/2026 | By News Bureau | 175
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Drug Discovery & Development | 16/02/2026 | By News Bureau | 173
US Food and Drug Administration has accepted the supplemental New Drug Application submitted by Biofrontera for its photodynamic therapy product Ameluz, used with the RhodoLED red-light lamp system, for the treatment of superficial basal cell carcinoma.
Drug Discovery & Development | 15/02/2026 | By Darshana | 177
Syngene Partners with Johns Hopkins University for Early Drug Discovery
The collaboration between Syngene International and John Hopkins University is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research.
Drug Discovery & Development | 13/02/2026 | By News Bureau | 214
Galderma Launches First OBT-Based Restylane Injectables in Japan
Galderma has launched Restylane Defyne and Restylane Refyne in Japan, marking the first authorization of hyaluronic acid injectables powered by its proprietary Optimal Balance Technology (OBT) in the country.
Drug Discovery & Development | 12/02/2026 | By Darshana | 211
Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026
Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.
Drug Discovery & Development | 12/02/2026 | By News Bureau | 433
Novo Nordisk Plans Wegovy Vial Launch to Expand Obesity Care Options
Danish drugmaker Novo Nordisk is planning to introduce vial presentations of its blockbuster obesity treatment Wegovy (semaglutide), expanding the range of delivery formats available for the therapy as competition intensifies in the weight-management market.
Drug Discovery & Development | 12/02/2026 | By Darshana | 239
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy